Cargando…

Editorial: Advances in Autoimmune Myasthenia Gravis

Detalles Bibliográficos
Autores principales:	Punga, Anna Rostedt, Kusner, Linda, Berrih-Aknin, Sonia, Le Panse, Rozen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484602/ https://www.ncbi.nlm.nih.gov/pubmed/32983085 http://dx.doi.org/10.3389/fimmu.2020.01688

Ejemplares similares

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker
por: Punga, Tanel, et al.
Publicado: (2014)

Autoimmune Thyroiditis and Myasthenia Gravis
por: Lopomo, Angela, et al.
Publicado: (2017)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models
por: Robinet, Marieke, et al.
Publicado: (2017)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine
por: Sabre, Liis, et al.
Publicado: (2020)

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019)

Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects
por: Truffault, Frédérique, et al.
Publicado: (2020)

Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
por: Cron, Mélanie A., et al.
Publicado: (2020)

Regulatory B cells in myasthenia gravis are differentially affected by therapies
por: Yilmaz, Vuslat, et al.
Publicado: (2018)

Altered expression of fragile X mental retardation-1 (FMR1) in the thymus in autoimmune myasthenia gravis
por: Thomas, Scott, et al.
Publicado: (2021)

Single-cell mass cytometry on peripheral cells in Myasthenia Gravis identifies dysregulation of innate immune cells
por: Verdier, Julien, et al.
Publicado: (2023)

Epidemiology of Myasthenia Gravis in Sweden 2006–2016
por: Westerberg, Elisabet, et al.
Publicado: (2020)

Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis
por: Weiss, Julia Miriam, et al.
Publicado: (2016)

Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs
por: Fiorillo, Alyson A., et al.
Publicado: (2020)

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis
por: Behin, Anthony, et al.
Publicado: (2018)

Myasthenia Gravis and Physical Exercise: A Novel Paradigm
por: O'Connor, Laura, et al.
Publicado: (2020)

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients
por: Molin, Carl Johan, et al.
Publicado: (2017)

Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
por: Villegas, José A., et al.
Publicado: (2023)

Thymectomy lowers the myasthenia gravis biomarker miR-150-5p
por: Molin, Carl Johan, et al.
Publicado: (2018)

Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023)

Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS
por: Meinen, Sarina, et al.
Publicado: (2012)

Cultured Human Thymic-Derived Cells Display Medullary Thymic Epithelial Cell Phenotype and Functionality
por: Villegas, José A., et al.
Publicado: (2018)

The impact of physical exercise on neuromuscular function in Myasthenia gravis patients: A single-subject design study
por: Westerberg, Elisabet, et al.
Publicado: (2018)

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
por: Maurer, Marie, et al.
Publicado: (2015)

Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases
por: Zhu, Ying, et al.
Publicado: (2023)

Comment on “Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis”
por: Le Panse, Rozen
Publicado: (2017)

Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats
por: Kaminski, Henry J., et al.
Publicado: (2016)

Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p
por: Beretta, Francesca, et al.
Publicado: (2022)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

Serum metabolomics of treatment response in myasthenia gravis
por: Sikorski, Patricia, et al.
Publicado: (2023)

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
por: Fichtner, Miriam L., et al.
Publicado: (2020)

Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats
por: Rinaldi, Elena, et al.
Publicado: (2019)

Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment
por: Sengupta, Manjistha, et al.
Publicado: (2014)

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis
por: Avidan, Nili, et al.
Publicado: (2014)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Muscle-Specific Kinase Myasthenia Gravis
por: Borges, Lucia S., et al.
Publicado: (2020)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sg87qdc9ji2iiregf24hn66lou